NVNOW
Get informed when a big investor buys or sells
+ FollowUndervalued by 2761.9% based on the discounted cash flow analysis.
| Market cap | $73.65 Million |
|---|---|
| Enterprise Value | $71.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-33.06 |
| Beta | 1.24 |
| Outstanding Shares | 654,000 |
| P/E Ratio | -0.39 |
|---|---|
| PEG | 2.71 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -3.59 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
No data
Hancock Jaffe Laboratories specializes in developing and manufacturing bioprosthetic (tissue-based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. HJLI currently has two lead product c...